日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

三阴性原发性骨髓纤维化:表型、基因型和预后的比较分析

Bashir, Yassin A; Abdelrheem, Ahmed A; Abdelmagid, Maymona; Reichard, Kaaren K; He, Rong; Zepeda Mendoza, Cinthya J; Pardanani, Animesh; Gangat, Naseema; Tefferi, Ayalew

NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance

骨髓纤维化中的NFκB/IL-6/JAK2/STAT通路是一个关键的脆弱点,可作为靶点,并与JAK2抑制剂治疗耐药性相关。

Bian, Huiqin; Gangat, Naseema; Shen, Na; Pang, Jiuxia; Wald, David; Tse, William; Tefferi, Ayalew; Yan, Fei; Liu, Shujun

One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol

慢性粒单核细胞白血病中TET2基因突变数量(1个、2个或≥3个):共突变模式及其在包括BLAST-mol和CPSS-mol在内的现代预后模型中的预后意义

Yousuf, Muhammad; Fathima, Saubia; Alsugair, Ali Khalid A; Wu, Samuel J; Abdelmagid, Maymona G; Patel, Shraddha P; Faldu, Priyansh C; Abdelaziz, Rania M; Csizmar, Clifford M; Mangaonkar, Abhishek A; Zepeda Mendoza, Cinthya J; Reichard, Kaaren K; Viswanatha, David S; He, Rong; Pardanani, Animesh; Gangat, Naseema; Patnaik, Mrinal S; Tefferi, Ayalew

A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns

慢性粒单核细胞白血病一线治疗策略的回顾性分析:对生存率和反应模式的影响

Yousuf, Muhammad; Faldu, Priyansh; Abdelmagid, Maymona; Aperna, Fnu; Fathima, Saubia; Alsugair, Ali Khalid A; Csizmar, Clifford M; Lasho, Terra L; Mangaonkar, Abhishek A; Reichard, Kaaren K; He, Rong; Pardanani, Animesh; Gangat, Naseema; Patnaik, Mrinal M; Tefferi, Ayalew

Patient-centered care strategies for Jehovah's Witnesses with acute leukemia and high-grade myeloid neoplasms

针对患有急性白血病和高级别髓系肿瘤的耶和华见证人的以患者为中心的护理策略

Zarka, Jabra; Al-Kali, Aref; Alkhateeb, Hassan B; Matin, Aasiya; Gangat, Naseema; Hogan, William J; Foran, James; Murthy, Hemant; Yi, Cecilia Arana; Prasad, Dhauna Karam; Mina, Syeda; Litzow, Mark R; Begna, Kebede H; Saliba, Antoine N

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias

克隆性造血和克隆性血细胞减少症患者中PPM1D突变的谱系、患病率和临床相关性

Badar, Talha; Marando, Ludovica; Latorre, Eric; Lasho, Terra; Olivia, Francyess Denis; Lin, Chenyu; McCormick, Benjamin J; El Kettani, Mobachir; Shah, Kashish J; Kusne, Yael; Jamy, Omer; Diebold, Kendall; Coltoff, Alexander; Finke, Christy; Foran, James; Kharfan-Dabaja, Mohamed; Fan, Yao-Shan; Jiang, Liuyan; He, Rong; Thomas, Miles; Patel, Anand; Viswanatha, David; Shah, Mithun Vinod; Saliba, Antoine; Mangaonkar, Abhishek; Kirschner, Kristina; Al-Kali, Aref; Gangat, Naseema; Litzow, Mark; Patnaik, Mrinal M

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation study

ELN 2022、ELN 2024 和 Beat AML 2024 治疗特异性预后性能:一项真实世界 AML 验证研究

Kewan, Tariq; Alkabbani, Oudai; Zureigat, Hadil; He, Rong; Jevremovic, Dragan; Greipp, Patricia; Saliba, Antoine; Matin, Aasiya; Torghabeh, Mehrdad Hefazi; Mangaonkar, Abishek; Gangat, Naseema; Hogan, William; Patnaik, Mrinal; Alkhateeb, Hassan; Yi, Cecilia Arana; Foran, James; Litzow, Mark; Shah, Mithun; Begna, Kebede; Al-Kali, Aref

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days

维奈托克治疗急性髓系白血病的疗程:7 天 vs 14 天 vs 21 天 vs 28 天

Gangat, Naseema; Tefferi, Ayalew

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort

在独立的国际队列中验证世界卫生组织和国际共识分类指南第五版中TP53突变型髓系肿瘤的分类标准

Shah, Mithun Vinod; Hung, Kevin; Baranwal, Anmol; Wechalekar, Gauri; Al-Kali, Aref; Toop, Carla R; Greipp, Patricia; Kutyna, Monika M; Matin, Aasiya; Ladon, Dariusz; Saliba, Antoine; Chen, Dong; Begna, Kebede; Brown, Anna; Rud, Danielle; Litzow, Mark R; Hogan, William J; Bardy, Peter; Badar, Talha; Kumar, Sharad; Yeung, David T; Patnaik, Mrinal M; Foran, James M; He, Rong; Gangat, Naseema; Hefazi, Mehrdad; Scott, Hamish S; Arana Yi, Cecilia Y; Alkhateeb, Hassan; Mangaonkar, Abhishek A; Thomas, Daniel; Hahn, Christopher N; Orazi, Attilio; Arber, Daniel A; Kok, Chung Hoow; Tefferi, Ayalew; Hiwase, Devendra

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

莫美替尼治疗未接受过JAK2抑制剂治疗的骨髓纤维化:利弊分析

Gangat, Naseema; Tefferi, Ayalew